Clinical Trial Update: Intralesional Treatment With Interleukin-2 (Proleukin) in Soft Tissue Melanoma Metastases [Phase 2]

View source ↗

Summary

Phase 2 trial update on intralesional interleukin-2 (Proleukin) for soft tissue metastases from melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Proleukin (aldesleukin)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Melanoma | Phase 2 | Status: COMPLETED